AbD Serotec, Dana-Farber Cancer Institute ink supply agreement
KIDLINGTON, U.K.—MorphoSys AG recently announced that its AbD Serotec unit has entered into a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. The DFCI is involved with research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense and is focused on developing transient immunity against life-threatening viral infections. Under the agreement, AbD Serotec will supply research tools using its proprietary Slonomics technology pieces to the laboratory of Dr. Wayne Marasco. In return, AbD Serotec will receive financial compensation and preferred access to commercialization rights for products resulting from the collaboration.